Protective effect of an aldose reductase inhibitor against bone loss in galactose-fed rats: Possible involvement of the polyol pathway in bone metabolism

Metabolism: Clinical and Experimental

Volumn 48, Issue 7, 1999, Pages 904-909

  Inaba, Masaaki ^a   Terada, Makoto ^a   Nishizawa, Yoshiki ^a   Shioi, Atsushi ^a   Ishimura, Eiji ^a   Otani, Shuzo ^a   Morii, Hirotoshi ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; BIOCHEMICAL MARKER; CALCIUM; GALACTOSE; POLYOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE ATROPHY; BONE MASS; BONE METABOLISM; CALCIUM METABOLISM; CONTROLLED STUDY; DIABETES MELLITUS; HYPERGLYCEMIA; MALE; MORPHOMETRICS; NONHUMAN; OSTEOLYSIS; OSTEOPENIA; PATHOGENESIS; PRIORITY JOURNAL; RAT; WEIGHT GAIN;

EID: 0032996189     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(99)90227-5     Document Type: Article

References (49)

1. Albright F, Reifenstein EC: Parathyroid Glands and Metabolic Bone Disease: Selected Studies. Baltimore, MD, Williams & Wilkins, 1948, pp 150-160
2. Levin ME, Boisseau VC, Avioli LV: Effect of diabetes mellitus on bone mass in juvenile and adult onset diabetes. N Engl J Med 294:241-244, 1976
3. Wu K, Schubeck KE, Frost HM: Haversian bone formation rates determined by a new method in human diabetes and osteoporosis. Calcif Tissue Res 6:204-219, 1970
4. Hough S, Avioli LV, Bergfeld MA, et al: Correction of abnormal bone and mineral metabolism in chronic streptozotocin-induced diabetes mellitus in the rat by insulin therapy. Endocrinology 108:2228-2234, 1981
5. Okuno Y, Nishizawa Y, Sekiya K, et al: Total and regional bone mineral content in patients with non-insulin dependent diabetes mellitus. J Nutr Sci Vitaminol 37:S43-S49, 1991 (suppl)
6. Imura H, Seino Y, Nakagawa S, et al: Diabetic osteopenia in Japanese - A geographic study. J Jpn Diabetes Soc 30:9929-9934, 1987
7. McNair P, Madsbad S, Christiansen C, et al: Bone loss in diabetes: Effects of metabolic state. Diabetologia 17:283-286, 1979
8. McNair P, Madsbad S, Christiansen C: Bone mineral loss in insulin treated diabetes mellitus; studies on pathogenesis. Acta Endocrinol (Copanh) 90:463-472, 1979
9. Gallagher JC, Melton LJ, Riggs BL: Examination of prevalence rates of possible risk factors in a population with a fracture of the proximal femur. Clin Orthop 153:158-165, 1980
10. Raskin P, Stevenson MR, Barilla DE, et al: The hypercalciuria of diabetes mellitus: Its amelioration with insulin. Clin Endocrinol (Oxf) 9:329-335, 1978
11. Silberberg R: The skeleton in diabetes mellitus; a review of the literature. Diabetes Res 3:329-338, 1986
12. Klein M, Frost HM: The numbers of bone resorption and formation in rib. Henry Ford Hosp Med Bull 12:527-536, 1964
13. Rico H, Hernandez ER, Cabranes JA, et al: Suggestion of a deficient osteoblastic function in diabetes mellitus. The possible cause of osteopenia in diabetics. Calcif Tissue Int 45:71-73, 1989
14. Krakauer JC, McKenna MJ, Buderer NF, et al: Bone loss and bone turnover in diabetes. Diabetes 44:775-782, 1995
15. Bouillon R, Bex M, Herck EV, et al: Influence of age, sex, and insulin on osteoblast function: Osteoblast dysfunction in diabetes mellitus. J Clin Endocrinol Metab 80:1194-1202, 1995
16. 3 in diabetic rats. Am J Physiol 265:E215-E223, 1993
17. 3 in patients with type 2 diabetes. Osteoporosis Int (in press)
18. Terada M, Inaba M, Yano Y, et al: Growth-inhibitory effect of a high glucose concentration on osteoblastic-like cells. Bone 22:17-23, 1998
19. 3-induced effect on human osteoblast-like MG-63 cells. J Bone Miner Res 10:1050-1056, 1995
20. Yoshida O, Inaba M, Terada M, et al: Impaired response of human osteosarcoma (MG-63) cells to human parathyroid hormone induced by sustained exposure to high glucose. Miner Electrolyte Metab 21:2201-2204, 1995
21. Terada M, Inaba M, Yoshida O, et al: Diabetic osteopenia; impaired proliferation in human osteoblast-like cell, MG-63, by high glucose. J Bone Miner Res S351, 1994 (suppl 1, abstr)
22. Berry GT: The role of polyols in the pathophysiology of hypergalactosemia. Eur J Pediatr 154:S53-S64, 1995 (suppl 2)
23. Robison WG Jr, Nagata M, Laver N, et al: Diabetic-like retinopathy in rats prevented with an aldose reductase inhibitor. Exp Eye Res 50:355-366, 1990
24. Kern TS, Engerman RL: Galatose-induced retinal microangiopathy in rats. Invest Ophthalmol Vis Sci 36:490-496, 1995
25. Cameron NE, Cotter MA, Rebertson S, et al: Muscle and nerve dysfunction in rats with experimental galactosemia. J Exp Physiol 77:89-108, 1992
26. Mizisin AP, Powell HC: Schwann cell injury is attenuated by aldose reductase inhibition in galactose intoxication. J Neuropathol Exp Neurol 52:78-86, 1993
27. Shindo H, Tawata M, Aida K, et al: The role of cyclic adenosine 3′,5′-monophosphate and polyol metabolism in diabetic neuropathy. J Clin Endocrinol Metab 74:393-398, 1992
28. 1H-NMR analysis of nerve edema in the streptozotocin-induced diabetic rat. J Lab Clin Med 124:627-637, 1994
29. Itagaki I, Shimizu K, Kamanaka Y, et al: The effect of an aldose reductase inhibitor (Epalrestat) on diabetic nephropathy in rats. Diabetes Res Clin Pract 25:147-154, 1994
30. Finch JL, Rapp N, Martin KJ, et al: A new sensitive homologous radioimmunoassay for amino-terminal parathyroid hormone in the rat. J Bone Miner Res 7:229-233, 1992
31. Cook JGH: Creatinine assay in the presence of protein. Clin Chim Acta 32:485-486, 1971
32. Uebelhardt D, Duboeuf F, Meunier PJ, et al: Lateral dual photon absorptiometry: A new technique to measure the bone mineral density at the lumber spine. Bone Miner 8:87-96, 1990
33. Lane NE, Kimmel DB, Nilsson MHL, et al: Bone-selective analogs of human PTH(I-34) increase bone formation in an ovariectomized rat model. J Bone Miner Res 11:614-625, 1996
34. Parfitt AM, Drezner MK, Glorieux FH, et al: Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Committee. J Bone Miner Res 2:595-610, 1987
35. Heaney RP: Nutrition and risk for osteoporosis, in Marcus R, Feldman D, Kelsey J (eds): Osteoporosis. San Diego, CA, Academic, 1996, pp 483-509
36. Imanishi Y, Koyama H, Inaba M, et al: Phosphorus intake regulates intestinal function and polyamine metabolism in uremia. Kidney Int 49:499-505, 1996
37. Nakayama K, Fukumoto S, Takeda S, et al: Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia. J Clin Endocrinol Metab 81:607-611, 1996
38. Engerman RL, Kern TS: Experimental galactosemia produces diabetic-like retinopathy. Diabetes 33:97-100, 1984
39. Glajchen N, Epstein S, Ismail F, et al: Bone mineral metabolism in experimental diabetes mellitus: Osteocalcin as a measure of bone remodeling. Endocrinology 123:290-295, 1988
40. Inaba M, Nishizawa Y, Shioi A, et al: Importance of high glucose condition in the development of diabetic osteopenia: Possible involvement of the polyol pathway. Osteoporos Int 7:S209-S212, 1997 (suppl 3)
41. Eastell R, Hampton L, Colwell A: Urinary collagen crosslinks are highly correlated with radioisotopic measurements of bone resorption, in Christiansen C, Overgaard K (eds): Proceedings of the Third International Symposium on Osteoporosis. Aalborg, Denmark, Osteopress, 1990, pp 469-470
42. Delmas PD, Schlemmer A, Gineyts E, et al: Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J Bone Miner Res 6:639-644, 1991
43. Brown JP, Delmas PD, Malaval L, et al: Serum bone Gla-protein: A specific marker for bone formation in postmenopausal osteoporosis. Lancet 1:1091-1093, 1984
44. Delmas PD, Malaval L, Arlot M, et al: Serum bone gla-protein compared to bone histomorphometry in endocrine diseases. Bone 6:329-341, 1985
45. Palmen E, Pedrazzoni M, Malaquinoo AM, et al: Osteocalcin levels in diabetes mellitus, in Christiansen C, Arnaud CD, Parfitt AM, et al (eds): Osteoporosis. Aalborg, Denmark, Aalborg Stiftsbogtrykkeri, 1984, pp 809-810
46. Ishida H, Seino Y, Taminato T, et al: Circulating levels and bone contents of bone γ-carboxyglutamic acid-containing protein are decreased in streptozotocin-induced diabetes: Possible marker for diabetic osteopenia. Diabetes 37:702-706, 1988
47. Tilton RG, Pugliese G, LaRose LS, et al: Discordant effects of the aldose reductase inhibitor, sorbinil, on vascular structure and function in chronically diabetic and galactosemic rats. J Diabetes Complications 5:230-237, 1991
48. Dvornik D, Millen J, Hicks D, et al: The pharmacokinetics of aldose reductase inhibitors, in Sakamoto N, Kinoshita JH, Kador PF, et al (eds): Polyol Pathway and Its Role in Diabetic Complications. The Netherlands, Amsterdam, Elsevier Science, 1988, pp 599-605
49. Sato S, Kador PF: NADPH-dependent reductases of the dog lens. Exp Eye Res 50:629-634, 1990